167 related articles for article (PubMed ID: 30979397)
1. Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study.
Suissa S; Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P
Semin Arthritis Rheum; 2019 Dec; 49(3):366-372. PubMed ID: 30979397
[TBL] [Abstract][Full Text] [Related]
2. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study.
Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P; Suissa S
Rheumatology (Oxford); 2020 Apr; 59(4):820-827. PubMed ID: 31504972
[TBL] [Abstract][Full Text] [Related]
3. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
[TBL] [Abstract][Full Text] [Related]
4. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
5. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
6. Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study.
Montastruc F; Renoux C; Hudson M; Dell'Aniello S; Simon TA; Suissa S
Semin Arthritis Rheum; 2019 Jun; 48(6):1053-1058. PubMed ID: 30772001
[TBL] [Abstract][Full Text] [Related]
7. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study.
Kang EH; Jin Y; Desai RJ; Liu J; Sparks JA; Kim SC
Semin Arthritis Rheum; 2020 Jun; 50(3):401-408. PubMed ID: 31813561
[TBL] [Abstract][Full Text] [Related]
8. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
Montastruc F; Renoux C; Dell'Aniello S; Simon TA; Azoulay L; Hudson M; Suissa S
Rheumatology (Oxford); 2019 Apr; 58(4):683-691. PubMed ID: 30535094
[TBL] [Abstract][Full Text] [Related]
9. Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.
Chen SK; Liao KP; Liu J; Kim SC
Arthritis Care Res (Hoboken); 2020 Jan; 72(1):9-17. PubMed ID: 30570833
[TBL] [Abstract][Full Text] [Related]
10. Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting.
Choi S; Ghang B; Jeong S; Choi D; Lee JS; Park SM; Lee EY
Semin Arthritis Rheum; 2021 Aug; 51(4):685-691. PubMed ID: 34139521
[TBL] [Abstract][Full Text] [Related]
11. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.
de Germay S; Bagheri H; Despas F; Rousseau V; Montastruc F
Rheumatology (Oxford); 2020 Sep; 59(9):2360-2367. PubMed ID: 31880308
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
13. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.
Kang EH; Jin Y; Brill G; Lewey J; Patorno E; Desai RJ; Kim SC
J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29367417
[TBL] [Abstract][Full Text] [Related]
14. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
15. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
16. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
17. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
Curtis JR; Yang S; Patkar NM; Chen L; Singh JA; Cannon GW; Mikuls TR; Delzell E; Saag KG; Safford MM; DuVall S; Alexander K; Napalkov P; Winthrop KL; Burton MJ; Kamauu A; Baddley JW
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):990-7. PubMed ID: 24470378
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial.
Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Bjørner JB; Hetland ML
Arthritis Rheumatol; 2019 Dec; 71(12):1997-2004. PubMed ID: 31268624
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]